Quinazoline compounds used to induce the breakdown of G12D mutant KRAS protein

Abstract

This invention provides a compound that can be used as an active ingredient in a pharmaceutical composition for the treatment of pancreatic cancer. The inventors conducted research on compounds that can be used as active ingredients in pharmaceutical compositions for the treatment of pancreatic cancer and discovered that quinazoline compounds possess excellent activity in inducing the degradation of G12D mutant KRAS protein and inhibiting G12D mutant KRAS, thus enabling their use as therapeutic agents for pancreatic cancer, thereby completing this invention. The quinazoline compound or its salt of this invention can be used as a therapeutic agent for pancreatic cancer.